InMed Pharmaceuticals Files 8-K
Ticker: INM · Form: 8-K · Filed: Apr 5, 2024 · CIK: 1728328
| Field | Detail |
|---|---|
| Company | Inmed Pharmaceuticals INC. (INM) |
| Form Type | 8-K |
| Filed Date | Apr 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k
TL;DR
InMed Pharma filed an 8-K, check for updates.
AI Summary
InMed Pharmaceuticals Inc. filed an 8-K on April 4, 2024, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporated in British Columbia, has its principal executive offices in Vancouver. No specific financial details or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates InMed Pharmaceuticals Inc. is providing updates to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain specific material events or financial data that would indicate a high-risk situation.
Key Players & Entities
- InMed Pharmaceuticals Inc. (company) — Filer
- Vancouver (location) — Principal Executive Offices
- British Columbia (location) — State of Incorporation
FAQ
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated April 4, 2024.
What is the company's state of incorporation?
The company is incorporated in British Columbia.
What is the SIC code for InMed Pharmaceuticals Inc.?
The Standard Industrial Classification code is 2834, Pharmaceutical Preparations.
What is the address of InMed Pharmaceuticals Inc.'s principal executive offices?
The address is Suite 310, 815 W. Hastings Street, Vancouver, B.C., Canada V6C 1B4.
What is the filing date of this 8-K report?
The filing date is April 5, 2024.
Filing Stats: 536 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-04-05 11:26:56
Filing Documents
- ea0203326-8k_inmed.htm (8-K) — 28KB
- ea020332601ex99-1_inmed.htm (EX-99.1) — 22KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001213900-24-030687.txt ( ) — 288KB
- inm-20240404.xsd (EX-101.SCH) — 3KB
- inm-20240404_def.xml (EX-101.DEF) — 26KB
- inm-20240404_lab.xml (EX-101.LAB) — 35KB
- inm-20240404_pre.xml (EX-101.PRE) — 24KB
- ea0203326-8k_inmed_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On April 4, 2024, the Company announced additional preclinical data demonstrating INM-901's positive pharmacological effects in the potential treatment of Alzheimer's disease ("AD"). The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits: The following exhibits shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 News release, dated April 4, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMED PHARMACEUTICALS INC. Date: April 4, 2024 By: /s/ Eric A Adams Eric A Adams President & CEO 2